Time to BCR and cancer-specific mortality after radiotherapy or prostatectomy: implications for risk stratification and follow-up

Key Points

• Cancer-specific mortality rates are crucial for understanding long-term patient outcomes, especially after prostate cancer treatment.
• The average time to biochemical recurrence (BCR) post-treatment helps guide follow-up protocols and patient management strategies.
• Analysis assessed outcomes after radiotherapy and prostatectomy, revealing differences in long-term cancer-specific mortality across treatment options.
• Risk stratification could improve patient care, suggesting personalized follow-up tailored to individual risk profiles based on treatment method.